BMC Infectious Diseases (Mar 2020)

Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire

  • Peter A. Minchella,
  • Christiane Adjé-Touré,
  • Guoqing Zhang,
  • Andre Tehe,
  • Judith Hedje,
  • Erin R. Rottinghaus,
  • Natacha Kohemun,
  • Micheline Aka,
  • Karidia Diallo,
  • G. Laissa Ouedraogo,
  • Kevin M. De Cock,
  • John N Nkengasong

DOI
https://doi.org/10.1186/s12879-020-4927-x
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Studies indicate that responses to HIV-2 treatment regimens are worse than responses to HIV-1 regimens during the first 12 months of treatment, but longer-term treatment responses are poorly described. We utilized data from Côte d’Ivoire’s RETRO-CI laboratory to examine long-term responses to HIV-2 treatment. Methods Adult (≥15 years) patients with baseline CD4 counts 75% of their recorded visits. Kaplan-Meier estimates for achievement of CD4 ≥ 500 cells/μl after 6 years of follow-up for patients in the lower CD4 strata (< 200 cells/μl) were 40% (HIV-1), 31% (HIV-dual), and 17% (HIV-2) (log-rank p < 0.001). Cox Regression indicated that HIV-1 was significantly associated with achievement of CD4 ≥ 500 cells/μl during follow-up, compared to HIV-2. Conclusions Sub-optimal responses to long-term HIV-2 treatment underscore the need for more research into improved and/or new treatment options for patients with HIV-2. In many West African countries, effective treatment of both HIV-1 and HIV-2 will be essential in the effort to reach epidemic control.

Keywords